TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8092235

Group type: EXPERIMENTAL
Intervention: Aggressive management
Number of subjects: 95

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 95
Study: 3133689

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Clomipramine and desmethylclomipramine
Number of subjects: 49
Study: 31085860

Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ringer's Lactate (RL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of Normal Saline and Ringer's Lactate (NS + RL)
Number of subjects: 90
Study: 27878780

Group type: EXPERIMENTAL
Intervention: Lactulose treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 30
Study: 26035756

Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 100
Study: 23756423

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mechanical preparation
Number of subjects: 10
Study: 22384542

Group type: EXPERIMENTAL
Intervention: Erhuang Powder (EHP) applied externally once every 3 days for 2 courses (5 applications per course)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Physiotherapy of the cervix (Control group)
Number of subjects: 64
Study: 19877980

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16428920

Group type: EXPERIMENTAL
Intervention: Ultrahaler (DPI) with doses of 130 and 360 microg/actuation
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDI (metered dose inhaler) with doses of 75 and 225 microg/actuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrahaler (DPI) with new dose strengths of 100, 225, and 450 microg/actuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro testing of DPI
Number of subjects: 0
Study: 15173268

Group type: EXPERIMENTAL
Intervention: Swedish snus
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: OMNI cigarettes
Number of subjects: 105
Study: 11300572

Group type: EXPERIMENTAL
Intervention: Chronic future-event expectancies (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporary, manipulated expectancy standards (Studies 2-4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive load condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cognitive load condition
Number of subjects: 0
Study: 9646423

Group type: EXPERIMENTAL
Intervention: Intensive counseling of infertile couples
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ligation or embolization of the spermatic vein
Number of subjects: 0
Study: 8181198

Group type: EXPERIMENTAL
Intervention: Fast infusion of temazepam (0.4 mg/kg in 30 minutes)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Slow infusion of temazepam (0.4 mg/kg in 120 minutes)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo control (vehicle infusion similar to fast infusion)
Number of subjects: 9
Study: 3422553

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 mL/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ethanol (1.1 mL/kg)
Number of subjects: 60
Study: 31427344

Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy plus movement sensor biofeedback
Number of subjects: 492

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 492
Study: 29652567

Group type: EXPERIMENTAL
Intervention: KAMUT khorasan products
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control wheat products
Number of subjects: 40
Study: 26851890

Group type: EXPERIMENTAL
Intervention: Food allergy handbook (handbook group)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (received handbook at conclusion of study)
Number of subjects: 153
Study: 25011986

Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) treatment
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Patients treated by orthopedic surgeons
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Patients with fractures prior to treatment initiation
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 829
Study: 22124575

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 20626727

Group type: EXPERIMENTAL
Intervention: Quetiapine (dosed up to 400 mg/d over 7 days, followed by 300 to 800 mg/d flexible dosing until study end)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 362
Study: 17355793

Group type: EXPERIMENTAL
Intervention: Saphenous vein preservation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saphenous vein ligation
Number of subjects: 64
Study: 15774791

Group type: COMPARATOR
Intervention: Standard chemotherapy (cisplatin, doxorubicin, high-dose methotrexate)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy + muramyl tripeptide (MTP)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy + ifosfamide
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy + ifosfamide + muramyl tripeptide (MTP)
Number of subjects: 677
Study: 11940756

Group type: EXPERIMENTAL
Intervention: RWJ‐67657 1400 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: RWJ‐67657 700 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: RWJ‐67657 350 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10072005

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 36
Study: 7722020

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 16 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Griseofulvin 500 mg/day for 52 weeks
Number of subjects: 89
Study: 2351367

Group type: EXPERIMENTAL
Intervention: 8 mg of perindopril tert‐butylamine salt by oral route (treatment A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous route (bolus in 5 min, treatment B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Equimolar dose of perindoprilat (6.1 mg) by intravenous route (infusion over 2 h, treatment C)
Number of subjects: 12
Study: 7014042

Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 75 g glucose
Number of subjects: 14
Study: 31867650

Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg nicotine/g tobacco)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal nicotine content cigarettes (15.8 mg/g)
Number of subjects: 58
Study: 27894373

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2 g/day for 24 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 26355134

Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based guidelines for CKD
Number of subjects: 27
Study: 25064019

Group type: EXPERIMENTAL
Intervention: $25 contingency management
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: $50 contingency management
Number of subjects: 26

Group type: COMPARATOR
Intervention: $0 condition
Number of subjects: 26
Study: 22291982

Group type: EXPERIMENTAL
Intervention: Total intermittent Pringle maneuver (total-IPM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Selective intermittent Pringle maneuver (sel-IPM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intermittent Pringle maneuver (no-IPM)
Number of subjects: 24
Study: 19174118

Group type: EXPERIMENTAL
Intervention: Heliox-driven nebulization of salbutamol or epinephrine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Oxygen-driven nebulization of salbutamol or epinephrine (control group)
Number of subjects: 96
Study: 17460158

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 220 mg BID
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 14693591

Group type: EXPERIMENTAL
Intervention: 30 mg 2-chloroprocaine with epinephrine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 45 mg 2-chloroprocaine with epinephrine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 60 mg 2-chloroprocaine with epinephrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: 30 mg 2-chloroprocaine without epinephrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: 45 mg 2-chloroprocaine without epinephrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: 60 mg 2-chloroprocaine without epinephrine
Number of subjects: 18
Study: 12352146

Group type: EXPERIMENTAL
Intervention: Triple-drug therapy
Number of subjects: 0
Study: 9834568

Group type: EXPERIMENTAL
Intervention: Simple drainage (3 patients)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Marsupialisation (3 patients)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Capitonnage (3 patients)
Number of subjects: 9
Study: 8719015

Group type: EXPERIMENTAL
Intervention: Diane 35
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Diane 50
Number of subjects: 58
Study: 1671603

Group type: EXPERIMENTAL
Intervention: Ipecacuanha-induced emesis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gastric lavage
Number of subjects: 30
Study: 350495

Group type: EXPERIMENTAL
Intervention: 1200 mg oxaprozin daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 600 mg oxaprozin daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin (3.9 g daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oxaprozin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 40
Study: 31422655

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.25% bupivacaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 10 mL of 1% lidocaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 5 mL of 0.25% bupivacaine plus 5 mL of 1% lidocaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 28537355

Group type: EXPERIMENTAL
Intervention: HARMONIC scalpel (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clamp, tie, and electrocautery (Group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 100
Study: 24375837

Group type: EXPERIMENTAL
Intervention: PPI treatment (14 days enteral omeprazole)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23850416

Group type: EXPERIMENTAL
Intervention: HSV vaccine (AS04-adjuvanted herpes simplex virus type 2 glycoprotein D subunit vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hepatitis A vaccine (Havrix™; HAV control)
Number of subjects: 0
Study: 21459215

Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Ranibizumab combined with laser
Number of subjects: 345

Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 345
Study: 19824016

Group type: EXPERIMENTAL
Intervention: 25 g unground flaxseed
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 25 g sesame seed
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 12.5 g unground flaxseed + 12.5 g sesame seed (flaxseed+sesame seed bar, FSB)
Number of subjects: 16
Study: 19242131

Group type: EXPERIMENTAL
Intervention: 40 mL/kg of fluid over 15 minutes followed by dopamine
Number of subjects: 147

Group type: COMPARATOR
Intervention: 20 mL/kg over 20 minutes up to a maximum of 60 mL/kg over 1 hour followed by dopamine
Number of subjects: 147
Study: 15198901

Group type: EXPERIMENTAL
Intervention: GOS supplemented formula (0.24 g/dl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control formula (without oligosaccharides)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GOS supplemented formula and human milk
Number of subjects: 0
Study: 12374874

Group type: EXPERIMENTAL
Intervention: Heparin plus alteplase
Number of subjects: 256

Group type: COMPARATOR
Intervention: Heparin plus placebo
Number of subjects: 256
Study: 10732800

Group type: EXPERIMENTAL
Intervention: CAG repeat genotyping in schizophrenia patients
Number of subjects: 219

Group type: COMPARATOR
Intervention: CAG repeat genotyping in bipolar I disorder patients
Number of subjects: 219
Study: 8078650

Group type: EXPERIMENTAL
Intervention: Reinforced zinc oxide eugenol (EBA) cement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 0
Study: 2644950

Group type: EXPERIMENTAL
Intervention: Cortisol dynamics abnormalities (fasting hypercortisolemia and absent diurnal variation)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cortisol response to dexamethasone suppression
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0800 cortisol levels
Number of subjects: 35
Study: 234668

Group type: EXPERIMENTAL
Intervention: Timolol (30 mg per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propranolol (120 mg per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11264555

Group type: EXPERIMENTAL
Intervention: Nesiritide (human recombinant B‐type natriuretic peptide)
Number of subjects: 1700
Study: 30527477

Group type: EXPERIMENTAL
Intervention: Touch Surgery (TS) application for simulation training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Written information (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall performance comparison
Number of subjects: 40
Study: 29438607

Group type: EXPERIMENTAL
Intervention: Intervention site (engagement of staff, education, electronic reminders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control site (no intervention)
Number of subjects: 0
Study: 27025337

Group type: EXPERIMENTAL
Intervention: Empirical tuberculosis therapy
Number of subjects: 850

Group type: COMPARATOR
Intervention: Isoniazid preventive therapy
Number of subjects: 850
Study: 24824310

Group type: EXPERIMENTAL
Intervention: Obinutuzumab + chlorambucil (GClb)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Chlorambucil alone (Clb)
Number of subjects: 238
Study: 22697273

Group type: EXPERIMENTAL
Intervention: Lobeglitazone (0.5 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Co-administration of Lobeglitazone and Metformin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lobeglitazone alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 24
Study: 20181679

Group type: EXPERIMENTAL
Intervention: Combined aspirin (25 mg BID) and extended-release dipyridamole (200 mg BID)
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 1360
Study: 17361245

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.5% timolol GFS
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost after switching from timolol GFS
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.5% timolol GFS after switching from latanoprost
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined treatment periods for latanoprost
Number of subjects: 75

Group type: COMPARATOR
Intervention: Combined treatment periods for timolol GFS
Number of subjects: 75
Study: 16379620

Group type: EXPERIMENTAL
Intervention: AIR pulmonary delivery system (5-mg placebo powder of engineered particles)
Number of subjects: 12
Study: 11927174

Group type: EXPERIMENTAL
Intervention: Olanzapine 5.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 1.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9860397

Group type: EXPERIMENTAL
Intervention: CCK-8 infused intravenously (i.v.) at physiological doses
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraduodenal (i.d.) oleate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK-A receptor antagonist) pretreatment
Number of subjects: 16
Study: 7658089

Group type: EXPERIMENTAL
Intervention: CVD 112 vaccine (10^6 cfu)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CVD 112 vaccine (10^8 cfu)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CVD 112 vaccine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Primary wild type clinical infection
Number of subjects: 12
Study: 2527546

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril and Hydrochlorothiazide (combination)
Number of subjects: 0
Study: 1104411

Group type: EXPERIMENTAL
Intervention: Prednisone 20 mg daily (Pred)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prednisone in doses given on alternate days and titrated (Pred‐Titrad)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of prednisone 10 mg and azathioprine 50 mg daily (Comb)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo or azathioprine 100 mg daily (Control)
Number of subjects: 120
Study: 31319810

Group type: EXPERIMENTAL
Intervention: Information
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Behavioural skills
Number of subjects: 380
Study: 28527657

Group type: EXPERIMENTAL
Intervention: Brief guided parent-delivered cognitive behavioural therapy (CBT)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Solution-focused brief therapy
Number of subjects: 136
Study: 27037096

Group type: EXPERIMENTAL
Intervention: Home-based Palliative HF Program (HPHP) implemented for up to 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (customary hospital-based care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based Palliative HF Program (HPHP)
Number of subjects: 0
Study: 24764200

Group type: COMPARATOR
Intervention: Paroxetine (10 mg/d) coadministration
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/d) coadministration
Number of subjects: 13
Study: 21981418

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 20048527

Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Number of subjects: 1674
Study: 17465663

Group type: COMPARATOR
Intervention: Kurasper F Bond (Conventional acid-etching and bonding system)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (Two-step fluoride-releasing antibacterial self-etching primer and adhesive)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clearfil tri‐S Bond (One-step self-etching primer and adhesive)
Number of subjects: 42
Study: 15045129

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg BW s.c. b.i.d.
Number of subjects: 90

Group type: COMPARATOR
Intervention: i.v. heparin aPTT‐adjusted daily for 8 +/- 2 days
Number of subjects: 90
Study: 11476774

Group type: EXPERIMENTAL
Intervention: ZIFT
Number of subjects: 548

Group type: COMPARATOR
Intervention: IVF-ET
Number of subjects: 548
Study: 9164891

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 20201

Group type: COMPARATOR
Intervention: No streptokinase allergy
Number of subjects: 20201
Study: 7962286

Group type: EXPERIMENTAL
Intervention: Prolonged dopamine infusion (5 micrograms/kg.min, iv)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Brief dopamine administration (15‐ to 21‐h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dopamine withdrawal
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 11
Study: 3604396

Group type: EXPERIMENTAL
Intervention: Live rubella vaccine
Number of subjects: 33
Study: 29659963

Group type: EXPERIMENTAL
Intervention: BUTTER (12.4-12.6% of energy as SFAs, 32% as fat, 52% as carbohydrates)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: MUFA (5.8% of energy as SFAs replaced with monounsaturated fatty acids from refined olive oil)
Number of subjects: 46

Group type: COMPARATOR
Intervention: CHEESE (12.4-12.6% of energy as SFAs, 32% as fat, 52% as carbohydrates)
Number of subjects: 46

Group type: COMPARATOR
Intervention: CHO (5.8% of energy as SFAs, 25.0% as fat, 59% as carbohydrates)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: BUTTER compared to CHEESE
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: MUFA compared to CHEESE
Number of subjects: 46
Study: 28161136

Group type: EXPERIMENTAL
Intervention: Diclofenac (50mg) with Codeine (50mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Diclofenac (50mg) alone
Number of subjects: 46
Study: 26335312

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral counseling (CBC)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Best practice (BP)
Number of subjects: 277
Study: 23312567

Group type: EXPERIMENTAL
Intervention: Iloperidone (24 mg/d, mean dose = 21.6 mg)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Iloperidone (12 mg/d, given once daily at bedtime)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 173
Study: 20829339

Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cycle exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Resting breathing (control)
Number of subjects: 14
Study: 18458356

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO(3)) 0.3 g/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caffeine 6.2 +/- 0.3 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of Sodium Bicarbonate and Caffeine (B+C)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 6
Study: 16918260

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0